Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Discussing whether a new $487M investment from the government will help speed up the production of the most important va...
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 05:24:01 30 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 05:24:01 30 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/30/2009 5:27:08 PM

RSS FEED

» Help

Current DateTime: 05:24:02 30 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Apr.02
11:13 AM ET
Wednesday, 2 Apr 2008
Pfizer's Failures--And Fight (For Lipitor)

Investors seem to be shrugging off another setback for drug giant Pfizer. Late yesterday the company announced it's stopping a late-stage clinical trial for a skin cancer drug because it looks like it doesn't work better than chemo.

You can read more about melanoma at the American Society of Clinical Oncology's brand new and improved web site (it just launched today).

Pharma investors should know the risks of drug development. Most products that get tested don't ever make it to market. And as we've seen in oh-so-many instances in recent years, even when they do get approved there's no guarantee that the results that were seen in big clinical trials are gonna hold up in the real world.

It's a risky business. But Pfizer [PFE  Loading...      ()   ] has had a run of bad luck, if you can call it that, lately. It started in late 2006 when its hoped-for successor to Lipitor failed. Then, late last year it paid billions of dollars to get out of the new, unsuccessful inhalable diabetic insulin business. Then, early this year safety issues cropped out for its new stop-smoking drug Chantix. And now this.

Miller-Tabak healthcare analyst Les Funtleyder writes in a research note to clients this morning: "Unfortunately the bad news continues for PFE and we do not see many positive catalysts in the near-term given pipeline issues and political headwinds; valuation and dividend (about a 6 percent yield) do provide some support on the downside however."

Goldman Sachs pharma analyst James Kelly had forecast $300 million in sales for the skin cancer drug in 2012. That's not huge for a company the size of Pfizer. But given the looming loss of the Lipitor patent and its relatively sparse drug development pipeline, the company needs every bit of new revenue it can generate.

So, Kelly is cutting his earnings estimate for 2012 by two cents. Goldman Sachs has done and wants to do more investment banking for PFE and it makes a market in the shares.

In the meantime, Pfizer is fighting for Lipitor. Take a look below at the new ad I mentioned in yesterday's post that the company has started running in the wake of the Vytorin/Zetia data that came out over the weekend. I don't recall ever seeing the image of a real heart--especially so prominently--in a drug ad like this one.

It's a stark contrast to Pfizer's recent Lipitor campaign with Dr. Robert Jarvik, the inventor of the artificial heart, that the company ended after the ads came under fire from several corners. So, perhaps PFE is going for a more science-driven, medical-driven look in the wake of that brouhaha.

The Pfizer news is also hurting shares of Medarex [MEDX  Loading...      ()   ] which would have received a royalty from PFE if the skin cancer drug worked. Pfizer says it is still testing it, though, on several other cancers.


The New York Post

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 05:22:42 30 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 11:44:56 30 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 04:05:27 30 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 11:23:57 30 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters